Issue 2, 2013

Novel FK506 and FK520 analogues via mutasynthesis: mutasynthon scope and product characteristics

Abstract

Novel FK506 and FK520 analogues were generated via biosynthetic engineering in order to generate analogue compounds with equal potency but improved pharmacological profiles compared to FK506. Strains suitable for mutasynthesis were produced by abolishing the activity of the rapK homolog fkbO, thereby disabling starter unit biosynthesis, and by replacing the polyketide synthase loading modules with the AT–ACP didomain equivalent from the avermectin PKS. A test set of FK506 and FK520 analogues was prepared and assessed for potency, physicochemical properties and pharmacokinetics, revealing that these compounds retain potency but are otherwise differentiated from the parent compounds.

Graphical abstract: Novel FK506 and FK520 analogues via mutasynthesis: mutasynthon scope and product characteristics

Supplementary files

Article information

Article type
Concise Article
Submitted
07 Sep 2012
Accepted
09 Nov 2012
First published
21 Nov 2012

Med. Chem. Commun., 2013,4, 324-331

Novel FK506 and FK520 analogues via mutasynthesis: mutasynthon scope and product characteristics

S. J. Moss, A. E. Stanley-Smith, U. Schell, N. J. Coates, T. A. Foster, S. Gaisser, M. A. Gregory, C. J. Martin, M. Nur-e-Alam, M. Piraee, M. Radzom, D. Suthar, D. G. Thexton, T. D. Warneck, M. Zhang and B. Wilkinson, Med. Chem. Commun., 2013, 4, 324 DOI: 10.1039/C2MD20266B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements